These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8962265)

  • 1. Suppression of T-cell-dependent immune responses in monkeys by CTLA4Ig.
    Cabrian KM; Berry KK; Shuford WW; Mittler RS; Rodgers JN; Linsley PS
    Transplant Proc; 1996 Dec; 28(6):3261-2. PubMed ID: 8962265
    [No Abstract]   [Full Text] [Related]  

  • 2. CTLA4Ig: effects on cellular and humoral immunity and macrophage activation.
    Schaub M; Stadlbauer TH; Sayegh MH
    Exp Nephrol; 1997; 5(5):370-4. PubMed ID: 9386972
    [No Abstract]   [Full Text] [Related]  

  • 3. CTLA4Ig Inhibits humoral and cellular immune responses to concordant xenografts.
    Ibrahim S; Xu R; Burdick JF; Baldwin W; Sanfilippo F; Kittur DS
    Transplant Proc; 1996 Apr; 28(2):715-6. PubMed ID: 8623361
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule.
    Linsley PS; Wallace PM; Johnson J; Gibson MG; Greene JL; Ledbetter JA; Singh C; Tepper MA
    Science; 1992 Aug; 257(5071):792-5. PubMed ID: 1496399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.
    Via CS; Rus V; Nguyen P; Linsley P; Gause WC
    J Immunol; 1996 Nov; 157(9):4258-67. PubMed ID: 8892665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation.
    Levisetti MG; Padrid PA; Szot GL; Mittal N; Meehan SM; Wardrip CL; Gray GS; Bruce DS; Thistlethwaite JR; Bluestone JA
    J Immunol; 1997 Dec; 159(11):5187-91. PubMed ID: 9548454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTLA4Ig inhibits airway eosinophilia and hyperresponsiveness by regulating the development of Th1/Th2 subsets in a murine model of asthma.
    Padrid PA; Mathur M; Li X; Herrmann K; Qin Y; Cattamanchi A; Weinstock J; Elliott D; Sperling AI; Bluestone JA
    Am J Respir Cell Mol Biol; 1998 Apr; 18(4):453-62. PubMed ID: 9533932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTLA4Ig-induced linked regulation of allogeneic T cell responses.
    Lee RS; Rusche JR; Maloney ME; Sachs DH; Sayegh MH; Madsen JC
    Transplant Proc; 2001; 33(1-2):88-9. PubMed ID: 11266718
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunosuppression and induction of anergy by CTLA4Ig in vitro: effects on cellular and antibody responses of lymphocytes from rats with experimental autoimmune myasthenia gravis.
    McIntosh KR; Linsley PS; Drachman DB
    Cell Immunol; 1995 Nov; 166(1):103-12. PubMed ID: 7585970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mounting a targeted strike on unwanted immune responses.
    Cohen J
    Science; 1992 Aug; 257(5071):751. PubMed ID: 1323142
    [No Abstract]   [Full Text] [Related]  

  • 11. Transplantation tolerance induced by CTLA4-Ig.
    Pearson TC; Alexander DZ; Winn KJ; Linsley PS; Lowry RP; Larsen CP
    Transplantation; 1994 Jun; 57(12):1701-6. PubMed ID: 8016872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of CTLA4lg (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses.
    Srinivas NR; Weiner RS; Warner G; Shyu WC; Davidson T; Fadrowski CG; Tay LK; Lee JS; Greene DS; Barbhaiya RH
    J Pharm Sci; 1996 Jan; 85(1):1-4. PubMed ID: 8926572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing allograft rejection with CTLA4IG: effect of donor-specific transfusion route or timing.
    Bolling SF; Lin H; Wei RQ; Turka LA
    J Heart Lung Transplant; 1996 Sep; 15(9):928-35. PubMed ID: 8889989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery of anti-CTLA-4 antibody downregulates T cell function in vitro and in vivo.
    Rao S; Vasu C; Martinez O; Kaithamana S; Prabhakar BS; Holterman MJ
    Clin Immunol; 2001 Nov; 101(2):136-45. PubMed ID: 11683572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig.
    Guérette B; Vilquin JT; Gingras M; Gravel C; Wood KJ; Tremblay JP
    Hum Gene Ther; 1996 Aug; 7(12):1455-63. PubMed ID: 8844205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new immunology--the end of immunosuppressive drug therapy?
    Schwartz RS
    N Engl J Med; 1999 Jun; 340(22):1754-6. PubMed ID: 10352169
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficient myoblast transplantation in mice immunosuppressed with monoclonal antibodies and CTLA4 Ig.
    Guérette B; Wood K; Roy R; Tremblay JP
    Transplant Proc; 1997 Jun; 29(4):1932-4. PubMed ID: 9193460
    [No Abstract]   [Full Text] [Related]  

  • 18. Feasibility of CTLA4Ig gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that induce alloantigen-specific T cell anergy in vitro.
    Takayama T; Morelli AE; Robbins PD; Tahara H; Thomson AW
    Gene Ther; 2000 Aug; 7(15):1265-73. PubMed ID: 10918497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA4-Fc treatment.
    Tran HM; Nickerson PW; Restifo AC; Ivis-Woodward MA; Patel A; Allen RD; Strom TB; O'Connell PJ
    J Immunol; 1997 Sep; 159(5):2232-9. PubMed ID: 9278311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment.
    Wallace PM; Rodgers JN; Leytze GM; Johnson JS; Linsley PS
    J Immunol; 1995 Jun; 154(11):5885-95. PubMed ID: 7751633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.